Omeros Co. (NASDAQ:OMER) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Omeros Co. (NASDAQ:OMER) have received an average rating of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $22.50.

Several equities analysts have issued reports on OMER shares. Rodman & Renshaw started coverage on shares of Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 target price on the stock. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Thursday, December 19th. D. Boral Capital started coverage on shares of Omeros in a research note on Monday, December 23rd. They set a “buy” rating and a $36.00 target price for the company. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a report on Thursday, November 14th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP purchased a new stake in Omeros in the third quarter worth about $305,000. Barclays PLC boosted its holdings in Omeros by 121.3% in the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock worth $376,000 after buying an additional 51,873 shares during the period. Bank of New York Mellon Corp increased its stake in Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after buying an additional 31,081 shares in the last quarter. AQR Capital Management LLC bought a new stake in Omeros during the second quarter valued at about $105,000. Finally, SG Americas Securities LLC purchased a new position in shares of Omeros in the third quarter valued at about $80,000. 48.79% of the stock is currently owned by institutional investors.

Omeros Trading Up 11.7 %

Omeros stock opened at $11.68 on Monday. The firm has a market cap of $676.86 million, a price-to-earnings ratio of -5.06 and a beta of 1.97. Omeros has a 12 month low of $2.61 and a 12 month high of $13.60. The stock has a fifty day simple moving average of $7.73 and a two-hundred day simple moving average of $5.43.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.